SCHEMBL18445707

SCHEMBL18445707

CCCC(n1c2ccccc2c2ccccc21)C(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.38
FFAR1 O14842 1/20 0.37
GPR84 Q9NQS5 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
PGR P06401 1/20 0.36
RORA P35398 1/20 0.36
RORC P51449 1/20 0.36
RORB Q92753 1/20 0.36
BACE1 P56817 2/20 0.35
ALDH1A1 P00352 2/20 0.34
SLC6A2 P23975 1/20 0.34
TSHR P16473 1/20 0.34
NPY1R P25929 1/20 0.34
NPY2R P49146 1/20 0.34
SIGMAR1 Q99720 2/20 0.33
HTR7 P34969 1/20 0.33
BCHE P06276 1/20 0.33
ACHE P22303 1/20 0.33
UTS2R Q9UKP6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13555375 0.84 GPR3 (0.36) GPR3CYP1A2CYP2C19PGRRORA
SCHEMBL13954491 0.80 GPR3 (0.39) GPR3GPR84CYP1A2CYP2C19BACE1
SCHEMBL23680180 0.79 GPR3 (0.38) GPR3CYP1A2CYP2C19BACE1ALDH1A1
SCHEMBL25823736 0.77 DNM1 (0.49) GPR3CYP1A2CYP2C19BACE1ALDH1A1
SCHEMBL574039 0.77 GPR3 (0.43) GPR3FFAR1GPR84CYP1A2CYP2C19
SCHEMBL21030063 0.76 GPR3 (0.39) GPR3CYP1A2CYP2C19PGRRORA
SCHEMBL13772400 0.76 CNR1 (0.43) GPR3CYP1A2CYP2C19PGRRORA
SCHEMBL25526924 0.74 GPR3 (0.40) GPR3FFAR1GPR84CYP1A2CYP2C19
SCHEMBL4729183 0.74 GPR3 (0.40) GPR3FFAR1GPR84CYP1A2CYP2C19
SCHEMBL18597053 0.72 GPR3 (0.46) GPR3CYP1A2CYP2C19BACE1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4329431-A2 NOVEL HETEROLEPTIC IRIDIUM COMPLEXES Universal Display Corporation (US) 2024-02-28 EP disclosed
EP-3882254-B1 PHOSPHORESCENT HOMOLEPTIC TRIS-[DEUTERATED-2(2-PYRIDINYL)PHENYL]-IRIDIUM COMPLEXES FOR USE IN LIGHT-EMITTING DEVICES UNIVERSAL DISPLAY CORP (US) 2023-10-04 EP disclosed
US-20230309376-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-09-28 US disclosed
EP-4223854-A2 PHOSPHORESCENT MATERIALS Universal Display Corporation (US) 2023-08-09 EP disclosed
EP-3424934-B1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORP (US) 2021-07-14 EP disclosed
EP-3505524-B1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORP (US) 2021-07-07 EP disclosed
EP-3220441-B1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORP (US) 2020-04-22 EP disclosed
EP-3547387-A1 ELECTROLUMINESCENT ELEMENT Universal Display Corporation (US) 2019-10-02 EP disclosed
EP-3505524-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES Universal Display Corporation (US) 2019-07-03 EP disclosed
EP-2910555-B1 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORP (US) 2019-03-27 EP disclosed
EP-3309155-A1 HOST MATERIALS FOR PHOLEDS Universal Display Corporation (US) 2018-04-18 EP disclosed
EP-2857409-B1 Novel Heteroleptic Iridium Complexes UNIVERSAL DISPLAY CORP (US) 2017-08-02 EP disclosed
EP-2329544-B1 WHITE PHOSPHORESCENT ORGANIC LIGHT EMITTING DEVICES UNIVERSAL DISPLAY CORP (US) 2017-05-17 EP disclosed
EP-2874195-B1 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORP (US) 2017-05-03 EP disclosed
EP-2718302-B1 HETEROLEPTIC IRIDIUM CARBENE COMPLEXES AND LIGHT EMITTING DEVICE USING THEM UNIVERSAL DISPLAY CORP (US) 2017-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230309376-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES ICOSLG, PDCD1LG2, NECTIN4 GPR3 3220/4885FFAR1 4634/4885GPR84 3495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.